Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques - PubMed (original) (raw)
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques
K J Stittelaar et al. Vaccine. 2001.
Abstract
Modified vaccinia virus Ankara (MVA)-based recombinant viruses have been shown to be potent vaccine candidates for several infectious and neoplastic diseases. Since a major application of these live, replication-deficient vectors would be their use in immunocompromised or potentially immunocompromised individuals, a preclinical safety study was carried out. Macaques were inoculated with high doses of MVA (10(9)) via various routes, after immune-suppression by total-body irradiation, anti-thymocyte globulin treatment, or measles virus (MV) infection. No clinical, haematological or pathological abnormalities related to MVA inoculation were observed during a 13-day follow-up period. The presence of MVA genomes was demonstrated by nested PCR during the course of the experiment in all macaques, but from none of these animals replication competent MVA could be reisolated. These data suggest that MVA can safely be used as a basis for recombinant human vaccines, and that it is also safe for use in immunocompromised individuals.
Similar articles
- Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.
Meseda CA, Atukorale V, Kuhn J, Schmeisser F, Weir JP. Meseda CA, et al. PLoS One. 2016 Feb 19;11(2):e0149364. doi: 10.1371/journal.pone.0149364. eCollection 2016. PLoS One. 2016. PMID: 26895072 Free PMC article. - Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
Ober BT, Brühl P, Schmidt M, Wieser V, Gritschenberger W, Coulibaly S, Savidis-Dacho H, Gerencer M, Falkner FG. Ober BT, et al. J Virol. 2002 Aug;76(15):7713-23. doi: 10.1128/jvi.76.15.7713-7723.2002. J Virol. 2002. PMID: 12097585 Free PMC article. - Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.
Sutter G, Staib C. Sutter G, et al. Curr Drug Targets Infect Disord. 2003 Sep;3(3):263-71. doi: 10.2174/1568005033481123. Curr Drug Targets Infect Disord. 2003. PMID: 14529359 Review. - Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.
Stittelaar KJ, van Amerongen G, Kondova I, Kuiken T, van Lavieren RF, Pistoor FH, Niesters HG, van Doornum G, van der Zeijst BA, Mateo L, Chaplin PJ, Osterhaus AD. Stittelaar KJ, et al. J Virol. 2005 Jun;79(12):7845-51. doi: 10.1128/JVI.79.12.7845-7851.2005. J Virol. 2005. PMID: 15919938 Free PMC article. - Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling.
Price PJ, Torres-Domínguez LE, Brandmüller C, Sutter G, Lehmann MH. Price PJ, et al. Vaccine. 2013 Sep 6;31(39):4231-4. doi: 10.1016/j.vaccine.2013.03.017. Epub 2013 Mar 21. Vaccine. 2013. PMID: 23523404 Review.
Cited by
- Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.
Earl PL, Americo JL, Wyatt LS, Eller LA, Montefiori DC, Byrum R, Piatak M, Lifson JD, Amara RR, Robinson HL, Huggins JW, Moss B. Earl PL, et al. Virology. 2007 Sep 15;366(1):84-97. doi: 10.1016/j.virol.2007.02.041. Epub 2007 May 11. Virology. 2007. PMID: 17499326 Free PMC article. - Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.
Wyatt LS, Earl PL, Vogt J, Eller LA, Chandran D, Liu J, Robinson HL, Moss B. Wyatt LS, et al. Vaccine. 2008 Jan 24;26(4):486-93. doi: 10.1016/j.vaccine.2007.11.036. Epub 2007 Dec 3. Vaccine. 2008. PMID: 18155813 Free PMC article. - Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.
Song GY, Srivastava T, Ishizaki H, Lacey SF, Diamond DJ, Ellenhorn JD. Song GY, et al. Cancer Invest. 2011 Oct;29(8):501-10. doi: 10.3109/07357907.2011.606248. Epub 2011 Aug 15. Cancer Invest. 2011. PMID: 21843052 Free PMC article. - Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases.
Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y, Wang T, Yan F, Yang S, Xia X. Wang S, et al. Signal Transduct Target Ther. 2023 Apr 7;8(1):149. doi: 10.1038/s41392-023-01408-5. Signal Transduct Target Ther. 2023. PMID: 37029123 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources